Hikal [HIKAL] vs Sequent Scientific [SEQUENT] Detailed Stock Comparison
Hikal
NSE
Loading...
Sequent Scientific
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Hikal wins in 15 metrics, Sequent Scientific wins in 3 metrics, with 0 ties. Hikal appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Hikal | Sequent Scientific | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 49.45 | 166.33 | Hikal |
| Price-to-Book Ratio | 2.48 | 6.61 | Hikal |
| Debt-to-Equity Ratio | 60.58 | 62.47 | Hikal |
| PEG Ratio | -0.09 | 1.40 | Hikal |
| EV/EBITDA | 13.08 | 30.63 | Hikal |
| Profit Margin (TTM) | 3.45% | 1.85% | Hikal |
| Operating Margin (TTM) | -3.76% | 7.56% | Sequent Scientific |
| EBITDA Margin (TTM) | N/A | 7.56% | N/A |
| Return on Equity | 7.19% | 2.84% | Hikal |
| Return on Assets (TTM) | 3.59% | 1.37% | Hikal |
| Free Cash Flow (TTM) | $1.43B | $442.73M | Hikal |
| Dividend Yield | 0.74% | N/A | N/A |
| 1-Year Return | -29.25% | -10.14% | Sequent Scientific |
| Price-to-Sales Ratio (TTM) | 1.71 | 3.00 | Hikal |
| Enterprise Value | $38.91B | $50.87B | Sequent Scientific |
| EV/Revenue Ratio | 2.12 | 3.17 | Hikal |
| Gross Profit Margin (TTM) | 49.69% | 46.86% | Hikal |
| Revenue per Share (TTM) | $149 | $64 | Hikal |
| Earnings per Share (Diluted) | $5.13 | $1.12 | Hikal |
| Beta (Stock Volatility) | 0.44 | 0.91 | Hikal |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Hikal vs Sequent Scientific Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Hikal | -0.37% | -0.41% | -5.17% | -26.85% | -40.31% | -36.94% |
| Sequent Scientific | 1.15% | -8.42% | 9.29% | -3.35% | 37.17% | 0.89% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Hikal | -29.25% | -24.34% | 43.57% | 219.28% | 337.49% | 203.52% |
| Sequent Scientific | -10.14% | 69.59% | 19.72% | 26.36% | 26.36% | 26.36% |
News Based Sentiment: Hikal vs Sequent Scientific
Hikal
News based Sentiment: NEGATIVE
September was a difficult month for Hikal, marked by a substantial loss in Q1 FY26 and a corresponding drop in share price. While positive regulatory audits and shareholder approvals offer some respite, the overall narrative is dominated by financial challenges and ongoing regulatory scrutiny, making it a significant month for investors to assess the company's trajectory.
Sequent Scientific
News based Sentiment: POSITIVE
Sequent Scientific's impressive Q1 FY2025-26 results, with a 21.9% revenue increase and a massive 1283.5% profit jump, clearly demonstrate a positive shift in the company's financial performance. This strong showing is a significant development for investors, indicating potential for future growth and returns.
Performance & Financial Health Analysis: Hikal vs Sequent Scientific
| Metric | HIKAL | SEQUENT |
|---|---|---|
| Market Information | ||
| Market Cap | ₹31.87B | ₹48.13B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 535,999 | 1,494,055 |
| 90 Day Avg. Volume | 521,218 | 754,164 |
| Last Close | ₹254.05 | ₹186.29 |
| 52 Week Range | ₹245.00 - ₹464.75 | ₹117.35 - ₹240.70 |
| % from 52W High | -45.34% | -22.60% |
| All-Time High | ₹742.00 (Aug 16, 2021) | ₹336.50 (Jun 28, 2021) |
| % from All-Time High | -65.76% | -44.64% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.07% | 0.13% |
| Quarterly Earnings Growth | -0.08% | 1.20% |
| Financial Health | ||
| Profit Margin (TTM) | 0.03% | 0.02% |
| Operating Margin (TTM) | -0.04% | 0.08% |
| Return on Equity (TTM) | 0.07% | 0.03% |
| Debt to Equity (MRQ) | 60.58 | 62.47 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹102.34 | ₹28.19 |
| Cash per Share (MRQ) | ₹1.46 | ₹2.52 |
| Operating Cash Flow (TTM) | ₹1.54B | ₹360.47M |
| Levered Free Cash Flow (TTM) | ₹908.00M | ₹218.78M |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.74% | N/A |
| Last 12-Month Dividend | ₹2.00 | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Hikal vs Sequent Scientific
| Metric | HIKAL | SEQUENT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 49.45 | 166.33 |
| Forward P/E | 19.74 | 36.89 |
| PEG Ratio | -0.09 | 1.40 |
| Price to Sales (TTM) | 1.71 | 3.00 |
| Price to Book (MRQ) | 2.48 | 6.61 |
| Market Capitalization | ||
| Market Capitalization | ₹31.87B | ₹48.13B |
| Enterprise Value | ₹38.91B | ₹50.87B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.12 | 3.17 |
| Enterprise to EBITDA | 13.08 | 30.63 |
| Risk & Other Metrics | ||
| Beta | 0.44 | 0.91 |
| Book Value per Share (MRQ) | ₹102.34 | ₹28.19 |
Financial Statements Comparison: Hikal vs Sequent Scientific
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | HIKAL | SEQUENT |
|---|---|---|
| Revenue/Sales | ₹3.71B | ₹4.41B |
| Cost of Goods Sold | ₹1.87B | ₹2.35B |
| Gross Profit | ₹1.85B | ₹2.07B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹-143.00M | ₹333.50M |
| EBITDA | ₹261.00M | ₹505.30M |
| Pre-Tax Income | ₹-304.00M | ₹255.20M |
| Income Tax | ₹-80.00M | ₹79.50M |
| Net Income (Profit) | ₹-224.00M | ₹175.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | HIKAL | SEQUENT |
|---|---|---|
| Cash & Equivalents | ₹130.00M | ₹626.60M |
| Total Current Assets | ₹9.95B | ₹8.74B |
| Total Current Liabilities | ₹7.90B | ₹5.05B |
| Long-Term Debt | ₹3.70B | ₹3.00B |
| Total Shareholders Equity | ₹12.62B | ₹7.70B |
| Retained Earnings | ₹9.67B | ₹1.25B |
| Property, Plant & Equipment | ₹403.00M | ₹2.84B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | HIKAL | SEQUENT |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | HIKAL | SEQUENT |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 535,999 | 1,494,055 |
| Average Daily Volume (90 Day) | 521,218 | 754,164 |
| Shares Outstanding | 123.30M | 249.89M |
| Float Shares | 38.07M | 118.88M |
| % Held by Insiders | 0.69% | 0.52% |
| % Held by Institutions | 0.07% | 0.13% |
Dividend Analysis & Yield Comparison: Hikal vs Sequent Scientific
| Metric | HIKAL | SEQUENT |
|---|---|---|
| Last 12-Month Dividend | ₹2.00 | ₹0.00 |
| Last 12-Month Dividend Yield | 0.74% | N/A |
| 3-Year Avg Annual Dividend | ₹1.40 | ₹0.00 |
| 3-Year Avg Dividend Yield | 0.20% | N/A |
| 3-Year Total Dividends | ₹4.20 | ₹0.00 |
| Ex-Dividend Date | Sep 02, 2025 | N/A |